Terray and Bristol Myers Squibb (NYSE: BMY) hit AI milestone using 13B+ binding data

Terray’s AI Platform Finds Drugs in Unseen Chemical Space, Achieves BMS Milestone

Terray Therapeutics has achieved its first discovery milestone in the company’s multi-target collaboration with Bristol Myers Squibb (BMS). Under the terms of the agreement, which began in 2023, Terray will discover and develop small molecule compounds against a set of targets nominated by BMS. BMS will subsequently assume responsibility for development and commercialization.  While therapeutic details of the milestone have not been disclosed, T…

Terray and Bristol Myers Squibb (NYSE: BMY) hit AI milestone using 13B+ binding data

Terray Therapeutics reaches a discovery milestone with BMS, leveraging its EMMI AI platform and 13B+ binding database to speed small molecule drug discovery.